FLT3 and acute myeloid leukemia: Iadademstat is also being evaluated in combination with Venetoclax and Azacitidine in newly diagnosed AML patients in an investigator-initiated phase I clinical trial at Oregon Health & Science University Knight Cancer Institute (NCT 06357182) and in a company-sponsored phase Ib clinical trial in combination with Gilteritinib in patients with R/R AML harboring FLT3 mutations (NC 05546580).